resTORbio, Inc. (TORC)
|Net Income (ttm)||-65.98M|
|Trading Day||Sep 16, 2020|
|Day's Range||14.56 - 16.09|
|52-Week Range||0.86 - 16.09|
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to preve...
resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform
NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a coll...
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-...
NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or th...
ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and we...
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash
The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.
There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.
Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upr...
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to pre...
TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.
As of late, it has definitely been a great time to be an investor in resTORbio.
resTORbio, a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to tr... [Read more...]
|IPO Date |
Jan 26, 2018
|Stock Exchange |
|Ticker Symbol |